CAIX PET/CT–guided radiation for clear cell kidney cancer
Official title: CAIX PET/ CT Guided Radiation Therapy in CcRCC.
Run by Peking University First Hospital · NCT07540260 · Data updated 2026-11-12
This trial will try using CAIX-targeted PET/CT scans plus FDG PET/CT to guide focused stereotactic radiation alongside standard targeted therapy and anti‑PD‑1 immunotherapy for adults with recurrent or metastatic clear cell kidney cancer.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 70 (estimated) |
| Sponsor | Peking University First Hospital Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | November 1, 2025 |
| Main results expected | December 31, 2030 |
| Study ends | December 31, 2030 |
| Registry record updated | April 20, 2026 |
| Trial ID | NCT07540260 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with histologically confirmed clear cell renal cell carcinoma that is recurrent or metastatic, who are on or planned for first-line targeted therapy plus anti‑PD‑1 immunotherapy, have access to dual PET/CT imaging, and have disease judged amenable to treating ≥75% of lesions with SABR.
✕Probably not a fit
Patients who cannot safely receive stereotactic radiotherapy, have uncontrolled serious comorbidities or active infection, are pregnant or breastfeeding, are unwilling or unable to comply with study procedures, or whose disease cannot be imaged or targeted sufficiently for SABR may not receive benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, single-arm study enrolling roughly 70 adults with recurrent or metastatic clear cell renal cell carcinoma who are receiving first-line targeted therapy combined with anti‑PD‑1 immunotherapy. Participants will undergo dual PET/CT imaging (FDG PET/CT and a CAIX-targeted PET/CT) to map disease sites and guide radiotherapy planning. When feasible, PET-visible lesions will be treated with image-guided stereotactic ablative radiotherapy (SABR), with a multidisciplinary team confirming that ≥75% of detectable lesions can be targeted. Patients will be followed for progression-free survival, local control of treated lesions, and treatment-related adverse events at a single center in Beijing.
Why it matters
Potential benefit: If successful, this approach could improve local control of metastatic lesions and potentially prolong progression-free survival by directing precise radiotherapy to biologically active tumors.
How similar studies have gone: Stereotactic ablative radiotherapy has shown promise for oligometastatic renal cell carcinoma in prior studies, but CAIX-targeted PET is a relatively new imaging approach with limited published outcome data to date.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Adults (≥18 years) Histologically confirmed clear cell renal cell carcinoma Recurrent or metastatic disease Planned or ongoing first-line systemic therapy (targeted therapy plus anti-PD-1 immunotherapy) Dual PET/CT imaging available (FDG PET/CT and CAIX-targeted PET/CT) and eligible for radiotherapy planning Multidisciplinary assessment confirms radiotherapy is feasible to treat ≥75% of detectable lesions Able to provide written informed consent Exclusion Criteria: Unable to receive stereotactic radiotherapy as planned Uncontrolled serious comorbidities or active infection Pregnant or breastfeeding Unable or unwilling to comply with study procedures and follow-up
Where it's running
-
Peking University First Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: Mingwei Ma
- Email: drmingweima@bjmu.edu.cn
- Phone: +86-13693556512
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Combining targeted therapy and immunotherapy with radiation for advanced kidney cancer
This study is testing if combining targeted therapy and immunotherapy with a specific type of radiation can help people with advanced kidney cancer live longer without their disease getting worse.
-
FAPI-guided radiotherapy with cadonilimab plus chemo for colorectal cancer limited to the peritoneum
Aims to see if adding targeted radiotherapy and cadonilimab immunotherapy to standard second-line chemotherapy helps adults with colorectal cancer that’s spread only to the peritoneum.
-
Pelvic ultra-hypofractionated radiotherapy after surgery for high-risk endometrial cancer
This trial tests whether giving 27.5 Gy in five sessions of pelvic radiotherapy after surgery is safe and feasible for high-risk endometrial cancer patients.
-
Radiation-related heart damage in locally advanced NSCLC tested with PET-CT
This study tests whether PET-CT imaging with 18F-Flurpiridaz can detect early radiation-related heart damage in adults with locally advanced non-small cell lung cancer receiving standard chemoradiation.
-
Seeing what cancer patients eat during radiation treatment using a mobile food diary
This study tests whether patients undergoing radiation therapy can consistently use a mobile food diary app to log their daily meals.
-
Radiation therapy options compared for newly diagnosed gynecologic cancers
This study tests whether proton therapy works as well as conventional photon therapy for endometrial and cervical cancers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.